Abstract
In phase 3 clinical trials for ceftobiprole treatment of complicated skin and skin structure infections, 1,219 gram-positive and 276 gram-negative aerobic baseline pathogens were identified. Ceftobiprole inhibited all staphylococcal isolates, including methicillin-resistant strains, at MICs of </=4 mug/ml. Against Enterobacteriaceae and Pseudomonas aeruginosa isolates, the potency of ceftobiprole was similar to that of cefepime.
Publication types
-
Clinical Trial, Phase III
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Cephalosporins / pharmacology*
-
Enterobacteriaceae / classification
-
Enterobacteriaceae / drug effects
-
Gram-Negative Bacteria / drug effects*
-
Gram-Negative Bacterial Infections / microbiology
-
Gram-Positive Bacteria / drug effects*
-
Gram-Positive Bacterial Infections / microbiology
-
Humans
-
Microbial Sensitivity Tests
-
Pseudomonas aeruginosa / drug effects
-
Skin Diseases, Bacterial / microbiology*
-
Staphylococcus / classification
-
Staphylococcus / drug effects
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
ceftobiprole